Ipamorelin: GH Secretagogue Without the Cortisol Spike

Ipamorelin is a pentapeptide growth hormone secretagogue that stimulates the pituitary gland to release growth hormone through the ghrelin receptor pathway. What distinguishes it from older secretagogues like GHRP-6 and GHRP-2 is its selectivity: ipamorelin raises GH without meaningfully increasing cortisol, prolactin, or ACTH — hormones that other secretagogues stimulate as unwanted side effects. This selectivity profile, combined with a well-characterized safety record in clinical trials, makes ipamorelin one of the most popular peptides for GH optimization.

How Ipamorelin Works

Ipamorelin binds to the GHSR-1a (growth hormone secretagogue receptor, subtype 1a) — the same receptor activated by ghrelin, the endogenous hunger hormone. Activation of GHSR-1a in the pituitary triggers a pulse of GH release.

Unlike exogenous human growth hormone (HGH) injections, which suppress the body's own GH production through negative feedback, ipamorelin stimulates the natural pulsatile secretion pattern. GH is normally released in pulses — highest during deep sleep, lower during waking hours — and ipamorelin amplifies these natural pulses rather than replacing them with a flat pharmacological level.

The selectivity advantage: GHRP-6 and GHRP-2 activate GHSR-1a but also bind to receptors on the adrenal gland and other tissues, causing cortisol and prolactin release. Ipamorelin's receptor binding is more restricted to the pituitary, which is why it does not meaningfully raise these hormones at standard doses.

Research Evidence

Ipamorelin has been studied in both animal and human trials. Key findings:

Phase I/II clinical trials (Novo Nordisk): Ipamorelin was developed by Novo Nordisk (as NNC 26-0161) and taken through phase I and II clinical trials. The trials demonstrated significant GH release and favorable safety/tolerability compared to earlier secretagogues. Development was eventually discontinued in favor of other pipeline drugs, not due to safety concerns.

Bone density: Animal studies in rats showed ipamorelin increased bone mineral density and bone formation markers more effectively than GHRP-6, attributed to its cleaner GH release without cortisol-mediated bone catabolism.

Body composition: GH-deficient rodent studies showed ipamorelin improved lean mass, reduced fat mass, and increased bone density in a dose-dependent manner.

GI motility: Ipamorelin accelerates GI motility in rat models — an effect shared with other ghrelin-receptor agonists and potentially beneficial for post-operative ileus. This was an area of clinical interest during development.

Dosage Protocol

Standard dosing:

• 200–300 mcg per injection
• 1–3 injections per day subcutaneously

Timing for GH optimization:

• Most important dose: 30–60 minutes before sleep (aligns with the natural GH surge during slow-wave sleep)
• Second dose: upon waking or mid-afternoon
• Third dose: pre-workout (GH release may enhance fat utilization during exercise)

Cycle length:

• Many practitioners use 3-month cycles
• Some use continuously at lower doses (200 mcg/night only)

Ipamorelin is typically reconstituted from lyophilized powder with bacteriostatic water at 1 mg/mL concentration. Inject subcutaneously in the abdomen or lateral thigh.

Ipamorelin Alone vs. With CJC-1295

Ipamorelin stimulates GH release by activating the GHSR-1a receptor (the ghrelin pathway). However, GH release is also regulated by GHRH (growth hormone releasing hormone) at the pituitary. CJC-1295 is a GHRH analog that works through a completely separate receptor (GHRH-R). Combining ipamorelin and CJC-1295 activates both pathways simultaneously, producing a synergistic GH pulse substantially larger than either peptide alone. This combination is covered in detail in a separate guide.

Using ipamorelin alone is appropriate for individuals who want a moderate, selective GH pulse without the amplified effect of a GHRH+GHRP combination.

Side Effects

Ipamorelin's selectivity profile minimizes the side effects seen with other secretagogues:

• Water retention: Common with GH elevation; typically mild with ipamorelin's moderate GH stimulus
• Hunger: Less than GHRP-6 (which causes significant appetite stimulation via ghrelin pathways); minimal at standard doses
• Tingling/numbness: Occasionally reported with GH peptide use; related to fluid shifts
• Injection site reactions: Minor redness or irritation
• Cortisol/prolactin elevation: Not observed at standard doses in clinical trials

No serious adverse events were reported in Novo Nordisk's clinical program.

Regulatory Status

Ipamorelin is not FDA-approved for any indication. It is sold legally in the United States for research purposes. WADA classifies it as a prohibited substance. It is not a controlled substance in the United States.

FAQ

Does ipamorelin cause hunger like GHRP-6? Hunger is a primary effect of GHRP-6 because it more strongly activates peripheral ghrelin receptors. Ipamorelin has minimal hunger-stimulating effects at standard doses, making it more practical for individuals who are not trying to increase caloric intake.

How do I know if ipamorelin is working? Increased sleep quality (more vivid dreams, deeper sleep) is often the first subjective sign. Over 4–8 weeks, improvements in body composition (reduced fat, improved muscle fullness) and recovery speed are typical indicators. IGF-1 blood levels can be measured to confirm GH axis activation.

Can women use ipamorelin? Yes. Women have GH secretion patterns that differ from men (generally higher GH pulse amplitude), and ipamorelin is appropriate for both sexes. Dosing is typically the same (200–300 mcg per injection).

Related Articles

• Growth Hormone Peptides: Complete Guide to GH Secretagogues
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It

Track your supplements in Optimize.